Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with

NCT Number	NCT06905054
Lead Sponsor	Mayo Clinic
Conditions	Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
Enrollment	80 participants
Start Date	2025-04-15
Primary Completion	2028-03-30 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-17